Advaxis, Inc. (NASDAQ:ADXS) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Friday.

A number of other analysts have also weighed in on the company. ValuEngine lowered Advaxis from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th. Cantor Fitzgerald set a $19.00 target price on Advaxis and gave the stock a “buy” rating in a report on Thursday, July 6th. Finally, HC Wainwright set a $23.00 target price on Advaxis and gave the stock a “buy” rating in a report on Wednesday, June 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $22.00.

Shares of Advaxis (ADXS) opened at 6.24 on Friday. Advaxis has a one year low of $5.70 and a one year high of $12.66. The company’s market cap is $252.48 million. The company’s 50-day moving average price is $6.50 and its 200 day moving average price is $7.68.

COPYRIGHT VIOLATION NOTICE: This piece was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2017/08/27/advaxis-inc-adxs-stock-rating-upgraded-by-bidaskclub.html.

A number of hedge funds have recently bought and sold shares of ADXS. The Manufacturers Life Insurance Company raised its stake in Advaxis by 10.4% in the second quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock worth $204,000 after buying an additional 2,969 shares in the last quarter. State Street Corp raised its stake in Advaxis by 7.8% in the second quarter. State Street Corp now owns 670,134 shares of the biotechnology company’s stock worth $4,352,000 after buying an additional 48,485 shares in the last quarter. DAFNA Capital Management LLC raised its stake in Advaxis by 43.6% in the second quarter. DAFNA Capital Management LLC now owns 247,000 shares of the biotechnology company’s stock worth $1,603,000 after buying an additional 75,000 shares in the last quarter. Nexthera Capital LP raised its stake in Advaxis by 160.3% in the second quarter. Nexthera Capital LP now owns 252,000 shares of the biotechnology company’s stock worth $1,635,000 after buying an additional 155,200 shares in the last quarter. Finally, Voya Investment Management LLC raised its stake in Advaxis by 20.3% in the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after buying an additional 2,975 shares in the last quarter. Institutional investors own 53.45% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.